Dizal got a lucky break with golidocitinib, and now mid-stage data back the project’s activity in T-cell lymphoma.

Blueprint looks to a next-gen Ayvakit, while Cogent challenges with a molecule acquired from Daiichi Sankyo.

Arvinas’s SERD appears to edge out Olema’s, but what’s the best CDK4/6 inhibitor for a phase 3 combination?

With inavolisib’s pivotal front-line win Roche reckons it can knock out Novartis’s Piqray.

Jaypirca secures a CLL label, though plans to dominate will be tempered by this market’s fast-changing nature.

Novartis' Jakafi faces competition from GSK's momelotinib, while Astra looks over its shoulder at Merck in biliary tract cancer. 

AstraZeneca and Lilly put PARP1 and KRAS G12C inhibitors into their first phase 3s, while Amgen advances DLL3 into early-stage disease.